Smith & Nephew/$SNN
1D1W1MYTD1Y5YMAX
Capital at risk
About Smith & Nephew
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.
- Ticker
- $SNN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 17,000
- Headquarters
- Watford, United Kingdom
- Website
- www.smith-nephew.com
Smith & Nephew Metrics
BasicAdvanced
$12B
38.61
$0.74
0.69
$0.75
3.29%
Price and volume
Market cap
$12B
Beta
0.69
52-week high
$37.78
52-week low
$27.23
Average daily volume
1.7M
Dividend rate
$0.75
Financial strength
Current ratio
2.139
Quick ratio
1.109
Long term debt to equity
0.62
Total debt to equity
0.731
Dividend payout ratio (TTM)
52.44%
Interest coverage (TTM)
6.59%
Profitability
EBITDA (TTM)
1,382
Gross margin (TTM)
68.44%
Net profit margin (TTM)
10.08%
Operating margin (TTM)
14.22%
Effective tax rate (TTM)
20.33%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
5.16%
Return on equity (TTM)
11.85%
Valuation
Price to earnings (TTM)
38.614
Price to revenue (TTM)
3.855
Price to book
1.72
Price to tangible book (TTM)
10.69
Price to free cash flow (TTM)
28.408
Free cash flow yield (TTM)
3.52%
Free cash flow per share (TTM)
1
Dividend yield (TTM)
2.65%
Forward dividend yield
3.29%
Growth
Revenue change (TTM)
5.99%
Earnings per share change (TTM)
31.78%
3-year revenue growth (CAGR)
5.61%
10-year revenue growth (CAGR)
3.00%
3-year earnings per share growth (CAGR)
43.34%
10-year earnings per share growth (CAGR)
6.37%
3-year dividend per share growth (CAGR)
1.92%
10-year dividend per share growth (CAGR)
2.41%
What the Analysts think about Smith & Nephew
Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.
Analyst projections of the future price of Smith & Nephew stock.
Bulls say / Bears say
First-half trading profit rose 8.1% to $566 million, surpassing analysts’ estimates and highlighting strong margin resilience despite softer revenue growth. (Reuters)
Smith & Nephew maintained full-year 2026 guidance unchanged, targeting around 6% underlying revenue growth, roughly 8% trading profit growth (~$1.3 billion post-acquisition), about $800 million of free cash flow, and over 10% adjusted ROIC, underscoring management’s confidence in its strategy. (SEC)
The company realised $130 million of efficiency savings in H1 2026 under its 12-Point Plan (cumulative savings of $330 million to date), driving profit growth and offsetting cost headwinds. (Reuters)
Second-quarter underlying revenue growth was only 1.6%, missing analysts’ 3.7% estimate and prompting a full-year revenue guidance cut to around 4% from about 6%. (Reuters)
U.S. knee implant sales declined 7.2% in Q2, reflecting softness in its core orthopaedics segment ahead of the launch of new cementless and kinematic products. (Reuters)
Advanced wound management performance is being offset by the reimbursement reset for skin substitutes, which is expected to pressure segment profitability in 2026. (LSE)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Smith & Nephew Financial Performance
Revenues and expenses
Smith & Nephew Earnings Performance
Company profitability
Upcoming events
Smith & Nephew News
AllArticlesVideos
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Accesswire1 week ago
Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism
Proactive Investors2 weeks ago
Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit
Proactive Investors2 weeks ago
Funds containing Smith & Nephew
AllGBPEURUSD
Fund name | Fund size | $SNN weighting |
|---|---|---|
Vanguard FTSE 100£VUKE | £4.8B | 0.38% |
Vanguard FTSE Developed Europe€VWCG | €3.1B | 0.09% |
Vanguard FTSE Developed Europe€VEUR | €4.8B | 0.09% |
Vanguard FTSE Developed Europe£VEUR | £4.1B | 0.09% |
Vanguard FTSE All-World High Dividend Yield€VHYL | €9.9B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.